Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.

Arrowhead Pharmaceuticals Inc (ARWR) reports robust clinical progress and commercial growth, despite a wider net loss in Q3 2026.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG), accelerating plans for a supplemental New Drug Application and highlighting continued growth in the launch of its REDEMPLO therapy for familial chylomicronemia syndrome (

Arrowhead Pharmaceuticals recently reported that its siRNA drug plozasiran met all primary and key secondary endpoints in two global Phase 3 trials for severe hypertriglyceridemia, while also completing patient enrollment for the YOSEMITE Phase 3 trial of zodasiran in the ultra-rare condition homozygous familial hypercholesterolemia. Together, these late-stage milestones highlight Arrowhead’s push to expand its RNAi portfolio into high-need cardiometabolic diseases, potentially broadening...

With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.

Chardan analyst Keay Nakae raised the firm's price target on Arrowhead to $115 from $90 and keeps a Buy rating on the shares.

Shares of Arrowhead Pharmaceuticals jumped 19% Wednesday after the company said its experimental drug, called plozasiran, sharply cut levels of triglycerides, a type of fat in the blood, in two late-stage trials aimed at patients with dangerously high levels of the fat. Plozasiran, given as a shot every three months, lowered triglycerides by as much as 81% after a year, compared with a drop of about 27% for patients on placebo. Arrowhead said it planned to ask the Food and Drug Administration by year-end to approve it for the larger population of patients with severe high triglycerides.

Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday, leading the stock to skyrocket.

Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and th

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) skyrocketed to a five-year high on Wednesday, as investors began positioning portfolios ahead of the supplemental new drug application (sNDA) of its drug candidate, plozasiran, for the treatment of severe hypertriglyceridemia. In intra-day trading, the stock soared by as much as 28 percent to a record high of $95.49—a level it […]

Arrowhead Pharmaceuticals (ARWR) said Wednesday topline results from its global phase 3 clinical stu

The biotech firm reported positive topline results from two Phase 3 studies evaluating its hypertriglyceridemia therapy.

Late-stage studies achieve all primary and secondary goalsArrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shares jumped 18% on Wednesday after the company announced positive topline data from its Phase 3 SHASTA-3 and SHASTA-4 clinical trials evaluating plozasiran in patients with severe hypertriglyceridemia.

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.

After a sharp 398.1% gain over the past year, Arrowhead Pharmaceuticals no longer looks obviously cheap, with its current valuation checks pointing to a more balanced picture rather than a clear bargain or clear excess. Arrowhead Pharmaceuticals' share price return of 398.1% over one year is extreme for a biotech stock and raises the bar for what needs to happen next to justify the move. The recent European Commission authorisation for Redemplo can support higher revenue expectations over...

EU authorisation of Redemplo expands targeted FCS treatment as the competitive apoC-III landscape continues to evolve.

Iran fired on ships, Trump answered with missiles and seized the Strait of Hormuz, and Wall Street spent Tuesday sorting out who gets hurt and who benefits. Analysts at KeyBanc, HSBC, and Mizuho made some bold calls you may not see coming.